The impact of PKR activation: from neurodegeneration to cancer
Identifiers
Identifiers
URI: http://hdl.handle.net/20.500.11940/8207
PMID: 24522206
DOI: 10.1096/fj.13-248294
ISSN: 0892-6638
Files view or download
Files view or download
Date issued
2014Journal title
FASEB JOURNAL
Type of content
Artigo
MeSH
Animals | Apoptosis | Cell Proliferation | Disease Progression | Gene Expression Regulation, Enzymologic | Humans | Inflammation | MicroRNAs | NF-kappa B | Neoplasms | Neurodegenerative Diseases | Phosphorylation | Prognosis | Protein Processing, Post-Translational | Tumor Suppressor Protein p53Abstract
An inverse association between cancer and neurodegeneration is plausible because these biological processes share several genes and signaling pathways. Whereas uncontrolled cell proliferation and decreased apoptotic cell death governs cancer, excessive apoptosis contributes to neurodegeneration. Protein kinase R (PKR), an interferon-inducible double-stranded RNA protein kinase, is involved in both diseases. PKR activation blocks global protein synthesis through eIF2alpha phosphorylation, leading to cell death in response to a variety of cellular stresses. However, PKR also has the dual role of activating the nuclear factor kappa-B pathway, promoting cell proliferation. Whereas PKR is recognized for its negative effects on neurodegenerative diseases, in part, inducing high level of apoptosis, the role of PKR activation in cancer remains controversial. In general, PKR is considered to have a tumor suppressor function, and some clinical data show a correlation between suppressed or inactivated PKR and a poor prognosis for several cancers. However, other studies show high PKR expression and activation levels in various cancers, suggesting that PKR might contribute to neoplastic progression. Understanding the cellular factors and signals involved in the regulation of PKR in these age-related diseases is relevant and may have important clinical implications. The present review highlights the current knowledge on the role of PKR in neurodegeneration and cancer, with special emphasis on its regulation and clinical implications.